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Abstract
Background: Globally, and particularly in developing countries, the menace of  anti-microbial resistance is an accelerating prob-
lem. In Nigeria, increase in bacterial resistance has been phenotypically established but due to high cost, few molecular studies 
have been reported. 
Objectives: This study screened for presence of  transferable resistance genes and mobile genetic elements (MGEs) such as 
integron among multi-drug resistant (MDR) P. mirabilis.
Methods: A total of  108 P. mirabilis strains collected from five tertiary hospitals in SouthWest Nigeria were subjected to antibi-
otic susceptibility study using disc-diffusion method. Transferable resistance genes and MGEs were amplified using Polymerase 
chain reaction (PCR) analysis and amplicons sequenced.
Results: Varied resistance was observed against all the antibiotics tested. About 56% of  the isolates were MDR including 
those from 0-12 years old children. PCR analysis revealed the presence of  aac(6’)-Ib (33.3%), plasmid mediated quinolone resis-
tance (PMQR) genes [qnrA (36.7%), acc(6’)-Ib-cr (5%)], TEM (48.3%), CTX-M (6.7%) and integrons class 1 (58.3%) and class 
2 (26.7%). Sequencing analysis revealed blaTEM-1, blaCTX-M-15 associated with ISEcp1 and eight different arrays of  gene cassettes: 
aadA1, aadA1-qacH, aadB-aadA2, aadA5, dfrA7, dfrA15, dfrA17, dfrA17-aadA5.
Conclusion: Transferable resistance genes in association with MGEs are present in Nigerian P. mirabilis thus their potential in 
disseminating resistance.
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Anti-microbial drug resistance has become a global con-
cern recognized by the World Health Organization1. Pro-
teus species, common inhabitants of  the soil and part of  
the normal flora of  the enteric region of  man and ani-
mals, have been found to cause opportunistic infections 
in several anatomical sites.2,3 Among the various species 
of  these genera, Proteus mirabilis is of  medical importance 
and usually responsible for most of  the common nos-
ocomial opportunistic infections such as urinary tract 
infections, wounds, ear and other infections.3 Their pos-
session of  a number of  virulence factors including anti-
biotic resistance genes, have placed the organism on the 
list of  medically important nosocomial agents.4,5,6,7,8 The 
micro-organism has been implicated in several nosocomi-
al infection outbreaks and community acquired infections 
in different parts of  the world, including Nigeria.9,10,11,12 
Among other antibiotics used in the treatment of  noso-
comial infections in Nigeria, the commonest classes of  
antibiotics usually employed for life threatening cases 
are the third generation cephalosporins, fluoroquinolo-
nes and aminoglycosides. However, several authors have 
reported resistance of  Enterobacteriaceae including Proteus 
mirabilis to these classes of  antibiotics.13,14,15,16
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Resistance to third generation cephalosporins has been 
attributed to the presence of  certain resistance determi-
nants called extended-spectrum beta-lactamase enzymes, 
ESBLs.17 Several variants of  these enzymes which were 
believed to have evolved from the wild-type beta-lact-
amases (TEM-1 and SHV-1) via mutation at one or more 
point in the gene coding for their amino acid sequence 
exist and are spread among bacterial isolates worldwide.17 
Another widely spread ESBL group are the CTX-M-type 
discovered in the 1980s in Munich, Germany from clini-
cal isolate of  Escherichia coli and currently five phylogroups 
exist.18 They are known to have high hydrolytic property 
against cefotaxime.18
Resistance to fluoroquinolones was initially thought 
to be majorly due to chromosomal mutation involving 
gyrA and topoisomerase genes until plasmid mediated 
quinolone resistance genes (PMQR) such as the qnr, qepA 
and aac(6’)-Ib-cr was later reported in 1998.19 Since then 
PMQR genes have been described in several bacterial iso-
lates particularly members of  the Enterobacteriaceae family 
worldwide.13,15,20,21,22 The qnr genes are known to produce 
proteins (QNR proteins) that protect the quinolone tar-
gets from inhibition. Studies have shown that they pro-
duce a low level resistance, but facilitate a higher level 
resistance in association with chromosomal mutations in 
bacteria harbouring them.23,24,25 The aac(6’)-Ib-cr, which 
encode a variant of  aminoglycoside transferase that con-
fers reduced susceptibility to ciprofloxacin and norfloxa-
cin by N-acetylation of  their piperazinyl amine, causes an 
increase in their MIC two to four fold26 and qepA gene, 
which encodes quinolone-specific efflux pump27 initiate 
decreased susceptibility to quinolones by up to 64-fold.28 
Resistance to aminoglycosides such as gentamicin, amik-
acin and tobramycin, have been attributed to the amino-
glycoside-modifying enzymes. Among the different class-
es of  these aminoglycoside-modifying enzyme that have 
been reported, the one encoded by the aac(6’)-Ib gene is 
the most commonly isolated in many clinical isolates par-
ticularly among the Enterobacteriaceae worldwide.13,15
Common resistance determinant genes that have been 
detected among isolates belonging to the Enterobacteriaceae 
family in Nigeria are ESBLs (TEM, CTX-M, SHV and 
OXA), AmpC Beta-Lactamase (CMY, DHA and ACT), 
plasmid-mediated quinolone resistance (qnrA, qnrB, qnrD, 
aac(6’)-Ib-cr and qepA) and aminoglycoside resistance 
(aac(6’)-Ib) genes.15,29 Most of  these resistant genes are 
acquired from other bacterial isolates through mobile ge-
netic elements such as integrons.
Integrons are composed of  three key elements: a gene 
encoding an integrase, a primary recombination site, and 
a promoter that directs the transcription of  captured 
genes.30 Integrase is involved in capturing of  resistance 
genes and incorporating them by site-specific recombina-
tion within the integrons conserved segments.30
The aim of  this study was to screen for the presence of  
common transferable resistance genes and mobile genetic 
elements such as integron and their associated gene cas-





A total of  108 non-duplicated clinical isolates of  P. mira-
bilis were randomly collected during a 12 months period 
(January to December, 2011) from Microbiology units 
of  five selected tertiary hospitals in SouthWest Nigeria, 
namely University Teaching Hospital (UCH) Ibadan (n 
= 43), Olabisi Onabanjo University Teaching Hospi-
tal (OOUTH) Sagamu (n = 10), Federal Medical Cen-
tre (FMC) Abeokuta (n = 13), Obafemi Awolowo Uni-
versity Teaching Hospital Complex (OAUTHC), Ile-Ife 
(n = 28) and Lagos state University Teaching Hospital 
(LUTH) Lagos (n = 14). The isolates were obtained from 
different clinical samples (wound, ear, eye, vaginal swabs, 
urine, sputum, peritoneal effluents, finger abscesses, pus 
and stool). They were identified by using Gram stain, 
MacConkey and Chocolate agar, swarming activity and 
confirmed with Microbact 12E Identification kit (Oxoid 
Ltd. Basingstoke, Hants, UK). Information on the pa-
tient’s data such as age, sex and specimen types was also 
recorded.
Antibiotic susceptibility test
The clinical isolates were subjected to antibiotic sus-
ceptibility testing against twelve antibiotics (Oxoid Ltd. 
Basingstoke, Hants, UK): amoxicillin (10µg), amoxicil-
lin-clavulanic acid (20/10µg), cefoxitin (30µg), ceftazi-
dime (30µg), cefotaxime (30µg), aztreonam (30µg), imipe-
nem (10µg), gentamicin (10µg), amikacin (30µg), nalidixic 
acid (30µg), ciprofloxacin (5µg), and trimethoprim-sul-
famethoxazole (25µg), using the disc-diffusion method. 
Minimum Inhibitory Concentrations (MICs) of  selected 
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antibiotics (cefotaxime, ceftazidime, amoxicillin-clavu-
lanic acid, ciprofloxacin and gentamicin) against selected 
MDR strains was done by broth micro-dilution using mi-
crotiter plates to further ascertain their level of  resistance. 
Interpretation was done by comparing results with Clini-
cal and Laboratory Standards Institute guidelines.31
Amplification of  common resistance genes
Clinical isolates that showed resistance to at least three 
classes of  antibiotics were regarded as MDR isolates32 
and were selected for amplification of  resistance genes 
using polymerase chain reaction (PCR) technique. 
Beta-Lactamase gene detection
MDR strains that showed resistance to third generation 
cephalosporins (cefotaxime and ceftazidime), aztreonam 
but were susceptible to cefoxitin were screened by sim-
plex PCR for blaTEM, blaSHV and blaCTX-M gene.
33,34,35 The 
CTX-M-positive strains were screened by simplex PCR 
for commonly associated insertion sequences (ISEcp1, 
IS26 and IS903) using them and blaCTX-M primer as for-
ward and reverse respectively.36 Those MDR isolates that 
showed resistance to the third generation cephalosporins, 
aztreonam and cefoxitin but were susceptible to imipen-
em were screened for common variants of  AmpC (blaCMY, 
blaDHA-1 blaFOX) and blaOXA that are usually found in Entero-
bacteriaceae using a multiplex PCR.37
Detection of  genes encoding plasmid mediated quinolone resistance 
(PMQR) and aminoglycoside-modifying enzyme (AAC).
MDR isolates with reduced susceptibility or resistance to 
quinolones and aminoglycosides were screened for the 
presence of  qnrA, qnrB, qnrS, qepA and aac(6’)-Ib genes 
using multiplex PCR.21 The aac(6’)-Ib amplicons were 
further digested with BstF5I (New England Biolabs, Ip-
swich, MA) and electrophoresed on 1% agarose gel to 
identify the aac(6’)-Ib-cr which lacks the BstF5I restriction 
site present in the wild-type aac(6’)-Ib gene.38
Detection of  classes 1, 2 and 3 Integrons and associ-
ated gene cassettes
All the MDR isolates were screened for the presence of  
classes 1, 2 and 3 integron-associated integrase genes us-
ing specific primers.39 The variable region of  the integrase 
positive strains were then amplified by PCR using specific 
primers to know if  they carry gene cassettes.39
Purification and sequencing of  amplified PCR prod-
ucts
The resulting PCR amplification products of  the detect-
ed beta-lactamase genes and the amplified variable region 
of  the integrons were purified using GF-1 PCR cleanup 
kit according to the manufacturer’s guidelines (Qiagen, 
Izasa, Portugal) and then sequenced in both forward and 
reverse nucleotide chains (Stabvida, Portugal) to identity 
the genes.
Conjugation assay for ESBL positive strains
The conjugation assay was performed using a modified 
method described by Kim et al. (2004).12 The ESBL pos-
itive donor strains were conjugated with the standard 
strain E. coli J53 (resistant to sodium azide) as a recipient 
cell. MacConkey agar containing 4 µg/mL of  cefotaxime 
and 200 µg/mL of  sodium azide was used as the selection 
medium. The growth of  the sodium azide resistant E. coli 
J53 in the selection plate was interpreted as an indication 
of  an ESBL embedded plasmid transfer. The transconju-
gants were confirmed by determining the antimicrobial 
susceptibility profile and PCR amplification.
Mutagenic treatment of  the isolates harbouring 
ESBL genes
Isolates harbouring ESBL genes were subjected to 
R-plasmid curing experiment using the modified meth-
od described by Adeleke et al. (2002).40 Briefly, the over-
night culture of  each ESBL-positive P. mirabilis strains 
was exposed to 200 and 100 μg/ml of  ethidium bromide 
and incubated for 24 hours at 370C. Pure colonies of  the 
ethidium bromide treated and untreated isolates were first 
selected on MacConkey agar plates and then on Nutrient 
agar, after which they were then diluted to 0.5 MacFar-
land standard for susceptibility testing against selected 
antibiotics (cefotaxime, ceftazidime, aztreonam, cipro-
floxacin, gentamicin and trimethoprim-sulphamethoxaz-
ole) by disc-diffusion method, and zones of  inhibition 
interpreted by comparing with the CLSI guideline.31
 
Results
Source of  bacterial isolates and antimicrobial sus-
ceptibility testing
Out of  108 clinical isolates of  P. mirabilis, 47 (43.5%) were 
from infected wounds, 24 (22.2%) from infected ears, 23 
(21.3%) from urine of  patients suffering from urinary 
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tract infections, 4 (3.7%) from infected vaginal swabs, 3 
(2.8%) from stool of  diarrheic patients, 2 (1.9%) from 
infected eye exudate, 1 (0.9%) from peritoneal effluent 
of  patient with kidney disease, 1 (0.9%) from sputum of  
patient with infected respiratory tract, and 1 (0,9%) from 
pus of  finger abscess. Twenty nine (26.9%) of  the isolates 
were obtained from children within the ages of  0 to 17 
years, 67 (62%) from patients within the ages 18 to 59 
years and 12 (11.1%) from patients above 60 years.
The result of  the anti-microbial susceptibility test showed 
that 80 (74.1%) of  the isolates were resistant to trimetho-
prim-sulfamethoxazole, 70 (64.8%) to amoxicillin, 58 
(53.7%) to nalidixic acid, 36 (33.3%) to cefotaxime, 29 
(26.9%) to gentamicin, 26 (24.1%) to ceftazidime, 17 
(15.7%) to amoxicillin-clavulanic acid, 16 (14.8%) to az-
treonam, 15 (13.9%) to ciprofloxacin,7 (6.5%) to cefoxi-
tin, 5 (4.6%) to amikacin and 2 (1.9%) to imipenem.
Sixty (55.6%) of  the isolates were classified as MDR since 
they were resistant to at least three classes of  antibiotics. 
Twelve (20%) of  these MDR isolates were from children 
within 0 – 12 years of  age suffering from various infec-
tions such as otitis media (50%), conjunctivitis (8.3%), 
burn wounds (25%), abscess (8.3%) and UTI (8.3%). 
The MICs of  the selected antibiotics against some of  the 




Patient’ Demography Antibiotic MIC (µg/mL) Resistant genes detected Gene cassette arrays





































































Pm 02 ECS 32 F >256 4 64 8 64 >256 + - - + + - - - - - - - +
Pm 03 Urine 50 F >256 4 64 8 64 >256 + - - + + - - - - + - - -
Pm 04 Urine 21 M >256 4 64 0.5 64 256 + - - + + - - - - - - - -
Pm 07 Ear pus 44 F >256 <0.25 32 0.5 0.5 1 - - - - - - - - + - - - -
Pm 09 Ear swabs 28 M >256 1 64 0.5 32 256 + - - + + - - - - - - - +
Pm 10 Urine 26 F >256 4 64 0.5 256 >256 + - - + + - - - - - - - +
Pm 12 Wound swabs 51 M >256 2 64 0.5 32 256 + - - + + - - - - - - + -
Pm 17 Wound swabs 14M M >256 2 64 >256 64 >256 + - - - + - - - - - - - +
Pm 20 Urine 28 M >256 4 64 0.5 256 >256 + - - + + - - - - - - - -
Pm 24 Ear swabs 112D F >256 2 64 0.5 64 256 + - - + + - - - - - - -
-
Pm 26 PE 22 F >256 2 64 0.5 256 >256 + - - + + - - - - - - - -
Pm 27 ECS 26 F >256 1 64 0.5 64 256 + - - + + - - - - - - -
Pm 30 Ear swabs 35 M >256 4 64 2 64 256 + - - + + - - - - - - - +
Pm 31 Ear swabs 2½ F >256 4 64 64 32 256 + - - + + - - - - - - - +
Pm 32 Urine 30 F >256 4 64 2 32 256 + - - + + - - - - - - - -
Pm 33 Urine 47 F >256 4 64 2 32 256 + - - + + - - - - - - - -
Pm 34 Urine 28 F >256 4 64 0.5 32 256 + - - + + - - - - - - - -
Pm 44 Wound swab 29 M >256 16 128 8 128 >256 - + + + - - - - - + - - -
Pm 47 Ear swabs 10 M >256 2 64 2 32 64 + - - + + - - - - - - - -
Pm 49 Ear swab 11 M >256 0.5 16 256 0.5 1 - - - - - + - - - - - - -
Pm 68 Wound swab 50 F >256 4 128 16 32 128 + - - + + - - - - - - - +
Pm 73 Wound swab 35 M >256 1 32 8 128 128 - - + - - - - - - + - - -
Pm 74 Wound swab 33 M >256 0.5 32 4 0.5 8 - - - - - - - - - - + - -
Pm 79 Wound swab 60 F >256 0.25 32 4 0.5 1 - - - - - - + - - - - - -
Pm 92 Urine 38 M >256 2 64 4 64 128 + - - - - - - - - - - - -
Pm 93 Wound swabs 55 F >256 0.5 128 4 64 64 - - - - + - - - - - - - -
Pm 94 Wound swabs 7 M >256 4 32 64 64 64 + - - - - - - - - - - - -
Pm 100 Wound swabs 36 F >256 16 256 16 128 128 + + + + - - - - - - - - -
Pm 107 Wound swabs 6 M >256 2 64 256 128 128 + - + + - - - + - - - - -
Pm 114 Wound swabs 55 F >256 2 128 8 32 32 - - - + + - - - - - - - -
Pm 116 Wound swabs 37 M >256 16 256 256 32 16 - + - + - - - - - - - - -
Table 1: Antibiotic susceptibility profile and resistant genes detected in multidrug resistant clinical isolates of Proteus mirabilis.
Key: ID – Identity, M – Male, F – Female, ECS – Endo-cervical swabs, PE – Peritoneal effluent, NA – Nalidixic acid, CIP – Ciprofloxacin, GN – Gentamicin, AMC –
Amoxicillin-clavulanic acid, CTX – cefotaxime, CAZ – ceftazidime, MICs – Minimum Inhibitory Concentrations, + – presence of gene, - – absence of gene, Yrs – Years, Pm 
– Proteus mirabilis.
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Antimicrobial resistance genes
Amplification and sequencing of  the beta-lactamase 
genes from the MDR strains resistant to cefotaxime 
or/and ceftazidime revealed that 29 (48.3%) harbored 
blaTEM-1 and 4 (6.7%) harboured blaCTX-M-15. The blaSHV, blaC-
MY, blaOXA, blaDHA-1 and blaFOX genes were not found. Two 
of  the blaCTX-M-15 genes were associated with ISEcp1. One 
of  the blaCTX-M-15 genes was detected from an MDR isolate 
collected from a six years old male child with an infected 
burn wound (Table 1).
Twenty (33.3%) of  the MDR isolates carried the aac(6’)-
Ib gene, including two isolated from a 2½ and 10 year 
old female and male patients, respectively, both suffering 
from ear infections (Table 1). The aac(6’)-Ib-cr and qnrA 
genes, associated with quinolone resistance, were present 
in 3 (5%) and 22 (36.7%) of  the MDR isolates, respec-
tively, while none was positive for qepA.
All (100%) MDR isolates harboured integrase genes, ei-
ther IntI1, IntI2 or both, among which 96.7% harboured 
IntI1, 53.3% IntI2, 51.7% carried both IntI1 and IntI2 
while none harboured IntI3. Amplification of  the inte-
grons variable region produced positive amplicons in 
76.7%, which included 58.3% and 26.7% of  the IntI1 and 
IntI2 positive strains respectively. Nine of  the children 
within the ages 0 and 12 years were infected with inte-
gron-positive MDR strains. Sequencing analysis revealed 
eight different gene cassette arrays (aadA1, aadA1-qacH, 
aadB-aadA2, aadA5, dfrA7, dfrA15, dfrA17 and dfrA17-aa-
dA5) spread among the integron positive MDR isolates. 
The gene cassette array dfrA17-aadA5 (47.1%) was the 
most common among the MDR isolates.
Conjugation and curing assays
The conjugation experiment performed with four 
CTX-M-15 strains did not yield any noticeable growth 
of  transconjugants in the selection plates. Moreover, the 
curing experiment did not alter the susceptibility profile 
of  the CTX-M-15 positive isolates to the cephalosporins 
and aztreonam significantly but rather increased the sus-
ceptibility of  the isolates to the effect of  the sulphame-
thoxazole-trimethoprim, gentamicin and to ciprofloxacin, 
as shown in Table 2. 
Table 2: Antibiotic susceptibility profiles of the mutagen treated and untreated CTX-M-15 
positive clinical isolates of MDR P. mirabilis 
 
Isolate ID 
Antibiotic Susceptibility Profile 
CTX CAZ AT CIP GN SXT 
Zones of growth inhibitions (mm) 
Untreated Clinical isolates of P. mirabilis 
Pm 044 R R S R R R 
Pm 073 R R S I R R 
Pm 100 R R S R R R 
Pm 107 R R S R R R 
Clinical isolates of P. mirabilis treated with 100µg/mL Ethidium bromide 
Pm 044 R R S S S S 
Pm 073 R R S I S S 
Pm 100 R R S S S S 
Pm 107 R R S R S S 
Clinical isolates of P. mirabilis treated with 200µg/mL Ethidium bromide 
Pm 044 R R S S S S 
Pm 073 R R S R S S 
Pm 100 R R S S S S 
Pm 107 R R S R S S 
  
Pm – Proteus mirabilis, S – Sensitive, I = Intermediate, R = Resistant, CTX = Cefotaxime, CAZ = Ceftazidime, 
ATM = Aztreonam, CIP = Ciprofloxacin, GN = Gentamicin, SXT = Sulphamethoxazole-trimethoprim. 
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All the primers used in the amplification of  the genes detected are presented in table 3.
Table 3: List of Primers used in this study 
 































471 M’Zali et al., 1996 
SH-R TCCCGCAGATAAATCACCA 
qnrA 
qnrA-F ATT TCT CAC GCC AGG ATT TG 
516 Kim et al., 2009 
qnrA-R GAT CGG CAA AGG TTA GGT CA 
qnrB 
qnrB-F GAT CGT GAA AGC CAG AAA GG 
476 Kim et al., 2009 
qnrB-R ATG AGC AAC GAT GCC TGG TA 
qnrS 
qnrS-F GCA AGT TCA TTG AAC AGG GT 
428 Kim et al., 2009 
qnrS-R TCT AAA CCG TCG AGT TCG GCG 
Target gene Primers Primer Sequence (5’- 3’) Amplicon size (bp) References 
OXA-1 variants 
OXA-F GGCACCAGATTCAACTTTCAAG 
564 Caroline et al., 2010 
OXA-R GACCCCAAGTTTCCTGTAAGTG 
DHA-1 variants 
DHA-1-  TGATGGCA GCAGGATATTC 





538 Caroline et al., 2010 
CMY-R ACGG CAG GTTAG ATA Y 
Multiplex FOX 
FOX-F CTACAGTGCGGGTGGTTT 
162 Caroline et al., 2010 
FOX-R CTATTTGCGGCCA TGA 
blaCTX-M 
CTX-M-F TTTGCGATGTGCAGTACCAGTAA 








471 M’Zali et al., 1996 
SH-R TCCCGCAGATAAATCACCA 
qnrA 
qnrA-F ATT TCT CAC GCC AGG ATT TG 
516 Kim et al., 2009 
qnrA-R GAT CGG AA AG  TTA GGT A 
qnrB 
qnrB-F GAT CGT GAA AGC CAG AAA GG 
476 Kim et al., 2009 
qnrB-R ATG AGC AAC GAT GCC TGG TA 
qnrS 
qnrS-F GCA AGT TCA TTG AAC AGG GT 
428 Kim et al., 2009 
qnrS-R TCT AAA CCG TCG AGT TCG GCG 
aac(6’)-Ib 
aacIb-F TTG CGA TGC TCT ATG AGT GGC TA 
482 Kim et al., 2009 
aacIb-R CTC GAA TGC CTG GCG TGT TT 
qepA 
qepA-F AAC TGC TTG AGC CCG TAG AT 
596 Kim et al., 2009 
qepA-R GTC TAC GCC ATG GAC CTC AC 
ISEcp1 ISEcp1 AAAAATGATTGAAAGGTGGT Variable Eckert et al., 2004 
IS26 IS26 AGCGGTAAATCGTGGAGTGA Variable Eckert et al., 2004 
IS903 IS903 CGGTTGTAATCTGTTGTCCA Variable Eckert et al., 2004 
IntI1 
Int 1-F CAG TGG ACA TAA GCC TGT TC 
160 Dillon et al., 2005 
Int 1-R CCC GAG GCA TAG ACT GTA 
IntI2 
Int 2-F CAC GCA TAT GCG ACA AAA AGG T 
788 Dillon et al., 2005 
Int 2-R GTA GCA AAC GAG TGA CGA AAT G 
IntI3 Int 3-F GCC TCC GGC AGC GAC TTT CAG 979 Dillon et al., 2005 
  Int 3-R ACG GAT CTG CCA AAC CTG ACT   
Class 1 array 
hep58 TCA TGG CTT GTT ATG ACT GT 
Varied Dillon et al., 2005 
hep59 GTA GGG CTT ATT ATG CAC GC 
Class 2 array 
hep74 CGG GAT CCC GGA CGG CAT GCA CGA TTT GTA 
Varied Dillon et al., 2005 
hep51 GAT GCC ATC GCA AGT ACG AG 
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Discussion
P. mirabilis is becoming a common opportunistic patho-
gen particularly within the Nigerian hospital setting.41 P. 
mirabilis is often associated with urinary tract infections 
especially among patients with long-term indwelling cath-
eters or under frequent antibiotic therapy.42,43 However, in 
this study, high occurrence in wound infections (43.5%) 
was found compared to urinary tract infections (21.3%) 
but a similar percentage occurred in ear infections (22%). 
Other studies performed in Nigeria, though with a lower 
number of  isolates, also reported a higher isolation of  P. 
mirabilis in wounds than in urine.3,15 The reason for the 
observed increased cases of  wounds infected with P. mi-
rabilis in previous and current studies cannot be explained 
but calls for serious caution in infection control program 
in these hospitals. Though the majority of  the patients 
(62%) were between the age of  18 and 59 years, about 
30% of  the isolates were recovered from infected chil-
dren less than 17 years (including newborn and children 
that were a few months old). This should be a worrisome 
development to healthcare professionals, highlighting 
that control of  nosocomial infection must be drastically 
improved in Nigerian tertiary hospitals.
The high frequency of  MDR phenotype observed among 
the P. mirabilis isolates in this study (55.6%) confirms ear-
lier reports that MDR is increasing in Nigeria among 
members of  the Enterobacteriaceae family.15 It is a concern 
to see that 20% of  the MDR isolates detected in this 
study are from children between the ages 0 and 12 years. 
This may not be surprising since various reports mention 
that self-medication of  children is rampant among nurs-
ing mothers, who usually take antibiotics irrationally even 
during breastfeeding.44,45,46,47
A low prevalence of  blaCTX-M-15 was found, (6.7%) con-
trary to the 27.3% prevalence of  blaSHV and blaCTX-M-15 re-
ported by Ogbolu et al.15 among 11 clinical P. mirabilis 
isolates from SouthWest Nigeria. Although blaCTX-M-15 has 
been previously described in clinical P. mirabilis isolates 
in Southwest Nigeria,15 this study reported ISEcp1 as-
sociated blaCTX-M-15 usually involved in the transposition 
of  the gene and its dissemination.48 The association of  
blaCTX-M-15 with mobile genetic elements such as insertion 
sequences and conjugative plasmids usually explain its 
worldwide dissemination. However, the conjugation as-
says performed in this study with all the CTX-M-15 posi-
tive strains did not produce any transconjugants suggest-
ing that it is not likely to be associated with conjugative 
plasmid. Furthermore, the R-plasmid curing experiments 
with ethidium bromide against these strains retained the 
resistance profile conferred by the blaCTX-M-15, this still sug-
gest a non-plasmid based gene. Although blaCTX-M-15 was 
already found within a chromosomal location associat-
ed with ISEcp1 in P. mirabilis strains isolated in Tunisia49 
and Korea,50 the two phenotypic experiment done in this 
study are inadequate to conclude a chromosomally based 
blaCTX-M-15. A molecular analysis, which was not the objec-
tive of  this study, is required to finally confirm the actual 
genetic location of  the blaCTX-M-15 detected in this study.
Plasmid mediated quinolone resistance (PMQR) genes 
are known to confer resistance to nalidixic acid and to 
increase the minimum inhibitory concentrations of  flu-
oroquinolones up to 32-fold or more.26 In this study, the 
detection of  qnrA and aac(6’)-Ib-cr associated with the 
reduced susceptibility to fluoroquinolones showed that 
these genes are spreading among clinical isolates in Ni-
geria. Previously, these genes have been reported in some 
Enterobacteriaceae in Nigeria, together with the qnrD gene 
variant which was not detected in this study.15
The aac(6’)-Ib gene is the most prevalent aminoglycoside 
modifying enzyme, conferring resistance to tobramycin, 
kanamycin and amikacin.51 The gene was first identified 
in Klebsiella pneumoniae isolates in 1986 and since then sev-
eral variants of  this enzyme have been described.26,51         
However, in this study, 3 (5%) of  the MDR isolates har-
boured  aac(6’)-Ib-cr, a variant of  the aac(6’)-Ib gene.
Of  relevance is the high prevalence of  MDR P. mirabilis 
strains with class 1 and 2 integrase genes, Intl1 and Intl2, 
and the occurrence of  eight different gene cassette arrays 
(aadA1, aadA1-qacH, aadB-aadA2, aadA5, dfrA7, dfrA15, 
dfrA17 and dfrA17-aadA5) within the variable region of  
the integrons in some of  the isolates. The size of  the 
amplicons (variable region) ranged from 300bp to 600bp 
depending on the type and number of  gene cassettes 
present. This result shows the potential of  these opportu-
nistic micro-organisms to acquire resistance genes, which 
is a threat for under-resourced countries, where more po-
tent antibiotics against MDR strains are usually expensive 
or inexistent.
Overall, accumulation of  resistant determinants through 
the activities of  mobile genetic elements is associated 
with the observed multidrug phenotype of  P. mirabilis 
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clinical isolates from SouthWest Nigeria. Our findings 
showed that these strains have the tools to acquire resis-
tance genes as much as possible. Therefore, strict surveil-
lance of  anti-microbial resistance, rational prescription 
of  antibiotics and strict laws to be enforced against over-
the-counter sales of  antibiotics must be implemented in 
Nigeria, to reduce to a minimum antibiotic resistance cas-
es in the country. The frequent isolation of  P. mirabilis in 
infected wounds in tertiary hospitals in Nigeria suggests 
the urgent need to review the existing infection control 
measures in hospital settings and to educate the clinical 
staff  on this scenario.
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